CSIR-Institute of Genomics and Integrative Biology

What CSIR-Institute of Genomics and Integrative Biology does

CSIR-Institute of Genomics and Integrative Biology (CSIR-IGIB) is a constituent government research laboratory under India's Council of Scientific and Industrial Research (CSIR), headquartered in New Delhi with a second campus on Mathura Road. Originally established in 1966 as the Centre for Biochemicals and renamed CSIR-IGIB in 2002 to align with the post-genome era, the institute conducts multidisciplinary research across genomics, molecular medicine, bioinformatics, proteomics, and multi-omics. It operates 40+ lead scientists supported by 450+ scholars and 250+ project staff, and runs state-of-the-art facilities including a GMP facility for ex-vivo gene therapy, the Phenome India National Biobank (10,000+ individuals; 6,000+ gut microbiome samples), Illumina MiSeq and NovaSeq sequencing platforms, a BSL-3 laboratory for tuberculosis research, one of India's largest zebrafish facilities, and HPC clusters for genomic data analysis.

CSIR-IGIB's translational technology portfolio centers on CRISPR-Cas9 applications. Its lead product is BIRSA101, an ex vivo CRISPR-Cas9 gene editing therapy for sickle cell anemia designed to reduce treatment cost from ₹20-25 crore to approximately ₹50 lakh and target underserved tribal populations in India, with Phase-I clinical trials expected in 2027. The institute developed FELUDA (FnCas9 Editor Linked Uniform Detection Assay), a CRISPR-based SARS-CoV-2 diagnostic demonstrating 100% sensitivity and 97% specificity with one-hour turnaround via a lateral flow strip read through the TOPSE smartphone app. Other patented platforms include the P149-mPEG350 thermoresponsive copolymer for rapid tumor spheroid formation (24-48 hours), a biomarker panel for triple-negative breast cancer prognosis, LC3 autophagy receptor mutants, and ligand-modified poly(beta amino) ester polymers for muscle-targeted gene delivery. The institute's work was instrumental in India's COVID-19 response through genomic surveillance, diagnostic deployment, and sero-surveys.

Commercially, CSIR-IGIB functions through structured industry engagement models rather than standard product pricing: sponsored research (industry-funded projects with CSIR-owned IP), collaborative research (jointly supported with shared IP), consultancy, grant-in-aid research, fee-based technical services (sequencing, multi-omics, HPC access), CSR-funded research, and technology licensing. Key partners include Serum Institute of India (exclusive technology transfer for BIRSA101), Tata Group (FELUDA commercialization), AIIMS (future clinical trial phases), WHO SEARO (regional genomics training), and Indian government bodies (CDSCO, ICMR, DBT, Ministry of Tribal Affairs, Niti Aayog) under the BioE3 Policy framework. The institute reported ₹150 Cr+ in cumulative research funding, ranked #4 globally in Biological Sciences in Nature Index 2025, and holds 420+ awards across 94 scientists over 25 years.

Name

CSIR-Institute of Genomics and Integrative Biology

Legal name

CSIR-Institute of Genomics and Integrative Biology

Website

https://igib.res.in

Company type

Private

Founded year

2002

Operating status

Operating

Headcount range

501–1,000 employees

Short description

CSIR-IGIB is an Indian government research institute under CSIR that develops CRISPR-based gene therapies (BIRSA101 for sickle cell anemia), CRISPR diagnostics (FELUDA for SARS-CoV-2), and operates the Phenome India National Biobank, serving Indian government bodies, pharmaceutical partners like Serum Institute of India, and international health organizations.

Ownership category

akta.pro rank

Product category

Genomics and Molecular Medicine Research Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511)

SIC

Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

CRISPR & Functional Genomics Screening Platforms (pooled/arrayed screens, perturb-seq) (HLAAAIAG)

akta.pro secondary industries

Molecular Diagnostics (PCR/qPCR, NGS-based assays) (HLAAALAA), Proteomics & Biomarker Analytical Testing (HLAGADAG), Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF)

Keywords

• Genomic research services
• CRISPR gene therapy
• Molecular diagnostics development
• Bioinformatics and proteomics
• Technology licensing partnerships

Headquarters

HQ city

New Delhi

HQ country

India

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Others

Revenue model

1. Grant-in-Aid Research: Projects where external agencies provide grants (full or partial) as cash or in-kind support for research activities, capacity building, and creation of national resources. Includes government funding agencies, international organizations.
2. Sponsored Research: Fully industry-funded R&D projects with clearly defined objectives, timelines, and deliverables. IP generated is owned by CSIR. Access to cutting-edge facilities for industry partners.
3. Collaborative Research: Jointly supported research with industry through financial or in-kind contributions. Shared IP ownership negotiated. Tailored governance with steering committees and milestones.
4. Consultancy: Expert outcome-oriented services including technical reports, feasibility studies, protocol development, data interpretation. Short-to-medium timelines with focused deliverables.
5. Technical Services: Fee-based access to advanced scientific infrastructure including sequencing platforms, multi-omics instrumentation, HPC clusters. Standardized, reproducible outputs with no IP terms.
6. CSR-Funded Research: Corporate Social Responsibility funded projects aligned with SDGs covering public health, environmental genomics, training, and outreach programs.
7. Technology Licensing: Licensing of patented technologies including P149-mPEG350 spheroid generation additive, BIRSA101 gene therapy, and FELUDA diagnostic system to pharmaceutical and biotech companies.

Go-to-market motion3 records

Distribution channels5 records

Marketing channels8 records

Core offering

CSIR-IGIB is a government research institute conducting R&D in genomics, molecular medicine, bioinformatics, and proteomics. It develops and licenses proprietary CRISPR-based technologies including the BIRSA101 ex vivo gene therapy for sickle cell anemia, the FELUDA CRISPR diagnostic for SARS-CoV-2, and the P149-mPEG350 thermoresponsive copolymer for tumor spheroid generation. The institute offers sponsored and collaborative research, consultancy, technical services, and technology licensing to pharmaceutical companies, government bodies, and academic partners.

Product overview

CSIR-IGIB operates as a research institute offering a portfolio of genomic technologies and services rather than a unified commercial product. Core offerings include BIRSA101 (indigenous CRISPR-based gene therapy for sickle cell anemia in partnership with Serum Institute) and FELUDA (CRISPR-based COVID-19 diagnostic). The institute provides access to state-of-the-art research facilities including GMP manufacturing for gene therapy, national biobanking through Phenome India, next-generation sequencing (MiSeq/NovaSeq), zebrafish model organism facility, BSL-3 containment for TB research, and spheroid generation technology (P149-mPEG350). Additional offerings include DNA sequencing, microarray, proteomics, and technical services for industry and academic partners.

Differentiator

Problem solved

Functional benefit

Products and services

• BIRSA101 CRISPR Gene Therapy
• FELUDA CRISPR Diagnostic
• P149-mPEG350 Thermoresponsive Copolymer
• Sponsored Research
• Collaborative Research
• Grant-in-Aid Research
• Consultancy Services
• Technical Services
• CSR-Funded Research
• Technology Licensing Portfolio

Quantifiable outcome

• Treatment cost reduction from ₹20-25 crore to ₹50 lakh for sickle cell disease gene therapy
• +5 more outcomes

Named customers5 records

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature6 records

Partnerships

Eight partnerships are on record, tiered core, flagship and minor.

• WHO SEARO (World Health Organization South-East Asia Regional Office)coreStrategic or Co-development Partner · 16 March 2026Co-hosting regional workshop on dengue genomics in New Delhi (March 16-20, 2026) to enhance genomic surveillance capacity in Southeast Asia. Training laboratory and public health professionals from Timor-Leste, Nepal, and Bhutan in viral sequencing, bioinformatics, and data analysis.
• Serum Institute of India (SIIPL)flagshipStrategic or Co-development Partner · 19 November 2025Strategic technology transfer agreement for BIRSA101 CRISPR-based gene therapy for sickle cell disease. Collaboration aims to reduce treatment cost from ₹20-25 crore to approximately ₹50 lakh. Part of India's mission to eradicate sickle cell anemia with support from Ministry of Tribal Affairs, Niti Aayog, and Ministry of Science and Technology.
• CDSCO, ICMR, DBT (Indian Regulatory Bodies)coreStrategic or Co-development Partner · 1 August 2024National regulatory bodies that have issued guidelines for gene therapy product development under India's BioE3 Policy. Phase-I clinical trial for Hemophilia A gene therapy demonstrated clinically significant outcomes. CSIR-IGIB executing technology transfer for gene therapy clinical translation.
• Ministry of Tribal Affairs, Niti Aayog, Ministry of Science and TechnologycoreStrategic or Co-development Partner · 1 August 2024Government stakeholders in India's sickle cell anemia eradication mission. Supporting GMP facility creation and BIRSA101 therapy development. Part of BioE3 Policy implementation to transform India into a global biomanufacturing hub.
• All India Institute of Medical Sciences (AIIMS)coreStrategic or Co-development PartnerFuture clinical trial phases planned in collaboration with AIIMS for BIRSA101 gene therapy. Joint conclaves and research collaboration between CSIR-IGIB and ACTREC (Advanced Centre for Treatment, Research and Education in Cancer).
• Multiple Pharmaceutical and Biotech CompaniescoreStrategic or Co-development PartnerActive Expressions of Interest for collaborations in areas including MRM-based proteomics, data platform development, breast cancer diagnostics, dengue severity detection, nutritional genomics, GMP container setup, and sequencing reagents development.
• Tata Group (FELUDA Commercialization)coreStrategic or Co-development PartnerPartnership with Tata for FELUDA diagnostic commercialization and digital solutions including TOPSE smartphone application for strip reading. BBC and CNN coverage of FELUDA test deployment.
• 3D Cell Culture Reagent and Kit ManufacturersminorChannel Partner/ Reseller/ DistributorLicensing opportunities for P149-mPEG350 spheroid generation additive to 3D cell culture reagent manufacturers, CROs for oncology screening, and pharma companies for predictive oncology platforms.

Scale indicators14 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Sherlock Biosciences: A US-based molecular diagnostics company pioneering CRISPR-based diagnostics (SHERLOCK and INSPECTR platforms). Directly comparable to IGIB's FELUDA CRISPR diagnostic, both leveraging CRISPR-Cas systems for nucleic acid detection in clinical and field-deployable formats.
• Mammoth Biosciences: A US-based CRISPR diagnostics company developing CRISPR-based detection platforms (DETECTR) for infectious diseases and other applications. Directly comparable to FELUDA's CRISPR-based diagnostic approach, both translating CRISPR biology into field-deployable molecular diagnostic tests.
• National Institute of Biomedical Genomics (NIBMG): An autonomous Indian institute focused on biomedical genomics research, with which IGIB has active joint research conclaves. Comparable as a government-funded Indian genomics research institution with similar mandate in population genomics, disease genomics, and translational research.
• CSIR-Centre for Cellular and Molecular Biology (CCMB): A peer CSIR constituent laboratory also based in Hyderabad, India, conducting research in cell biology, molecular biology, genomics, and biotechnology. Directly comparable as a sister CSIR institution with similar government mandate, scientific scope, and industry partnership model in life sciences.
• Advanced Centre for Treatment, Research and Education in Cancer (ACTREC): A TMC-affiliated Indian cancer research centre that has formal research conclaves with CSIR-IGIB. Comparable as an Indian translational research institution with focus on molecular medicine, cancer genomics, and CAR-T cell therapy research - directly overlapping IGIB's biomarker panel work for triple-negative breast cancer.

Broad incumbents

• Indian Institute of Science (IISc): India's premier research and graduate education institution with significant life sciences and biotechnology research programs. Comparable as a leading Indian government research institution with overlapping capabilities in genomics, molecular biology, and translational biotechnology, though broader in scope than IGIB.
• CRISPR Therapeutics: A leading commercial gene editing company with Casgevy (the first FDA-approved CRISPR-based therapy, co-developed with Vertex for sickle cell disease). Directly comparable to IGIB's BIRSA101 since both target sickle cell disease via CRISPR-Cas9 gene editing, though CRISPR Therapeutics operates at commercial scale with global reach while IGIB is a research-stage government institute.

Emerging players

• Strand Life Sciences: An Indian bioinformatics and clinical genomics company providing genomic testing, bioinformatics services, and clinical interpretation. Comparable as an India-based genomics company that translates research into clinical applications, though operating as a commercial entity rather than government research institute.
• MedGenome: A leading India-headquartered genomics and clinical diagnostics company focused on genetic testing, molecular diagnostics, and population genomics. Comparable through its emphasis on India-specific population genomics data, similar to IGIB's Phenome India Biobank mission, though commercially driven.

Regional players

• Institute of Bioinformatics and Applied Biotechnology (IBAB): An Indian bioinformatics and biotechnology research institution based in Bangalore with focus on genomics, computational biology, and biotech training. Comparable as an Indian research entity operating in overlapping genomics and bioinformatics domains, though more specialized in computational aspects.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/igibsocial
• YouTubeyoutube.com/c/IGIBSocial
• Facebookfacebook.com/igibofficial
• LinkedInlinkedin.com/company/igib-social
• Instagraminstagram.com/igibsocial

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CSIR-Institute of Genomics and Integrative Biology